



29<sup>th</sup> October 2025

The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001  
Scrip Code: 500674

The Secretary  
The National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra East,  
Mumbai 400 050  
Symbol: SANOFI

**Sub: Outcome of the Board Meeting of the Company held on Wednesday, 29<sup>th</sup> October 2025**

Dear Sir / Madam,

We refer to our intimation dated 23<sup>rd</sup> October 2025, informing about the Board Meeting scheduled for today. In this regard, we wish to inform you that the Board of Directors, at its meeting held today, i.e., Wednesday, 29<sup>th</sup> October 2025, *inter-alia* considered and

- Approved the Unaudited Financial Statements for the quarter and nine-months ended 30<sup>th</sup> September 2025.

Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Statements for the quarter and nine-months ended 30<sup>th</sup> September 2025 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid financial results will also be available on the Company's website on [Financial results - Sanofi India](#).



- Declared an Interim Dividend of Rs. 75 per equity share of the face value of Rs. 10 each for the year 2025, which will be paid within 30 days from the date of declaration. The Company has fixed Friday, 7<sup>th</sup> November 2025 as the “Record Date” for the payment of Interim Dividend.

The meeting of Board of Directors commenced at 9:30 a.m. and concluded at 1:03 p.m.

Please take the above information on record.

Thanking you,

Yours faithfully

**For Sanofi India Limited**

**Haresh**  
**Bachubh**  
**ai Vala**

Digitally signed  
by Haresh  
Bachubhai Vala  
Date: 2025.10.29  
13:21:32 +05'30'

**Haresh Vala**

**Company Secretary and Compliance Officer**

**Membership No.: A18246**

# Price Waterhouse & Co Chartered Accountants LLP

## Review Report

To  
The Board of Directors  
Sanofi India Limited  
CTS No. 117-B, L&T Business Park,  
Saki Vihar Road, Powai,  
Mumbai 400 072

1. We have reviewed the unaudited financial results of Sanofi India Limited (the "Company") for the quarter ended September 30, 2025 and the year to date results for the period January 01, 2025 to September 30, 2025, which are included in the accompanying Statement of Unaudited Financial Results for the quarter and nine months ended September 30, 2025 (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP  
Firm Registration Number: 304026E/E-300009  
**ARUNKUMAR**  
**RAMDAS**  
Arunkumar Ramdas  
Partner  
Membership Number: 112433  
UDIN: 25112433BMOVAY1574

Digitally signed by  
ARUNKUMAR RAMDAS  
Date: 2025.10.29 13:11:55  
+05'30'

Place: Mumbai  
Date: October 29, 2025

Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park,  
Dadar (West) Mumbai - 400 028  
T: +91 (22) 66697508

Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

# SANOFI INDIA LIMITED

Registered Office : Sanofi House,C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.  
Corporate Identity Number: L24239MH1956PLC009794  
Tel no: (91-22) 28032000 Fax No: (91-22) 28032846  
Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025

Particulars	₹ in Million					
	Quarter ended 30.09.2025	Quarter ended 30.06.2025	Quarter ended 30.09.2024	Nine Months ended 30.09.2025	Nine Months ended 30.09.2024	Year ended 31.12.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited) (Refer Note 3)	(Audited) (Refer Note 3)
<b>Continuing Operations</b>						
1. Revenue from Operations	4,754	4,063	5,240	14,176	14,983	20,132
2. Other Income	49	87	23	169	106	165
3. Total Income (1+2)	4,803	4,150	5,263	14,345	15,089	20,297
4. Expenses						
(a) Cost of Materials Consumed	533	621	931	1,911	2,521	3,548
(b) Purchases of stock in trade	2,698	356	2,018	3,895	3,258	5,643
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	(832)	1,110	(349)	1,085	1,516	602
(d) Employee benefits expense	419	449	567	1,406	1,864	2,402
(e) Finance costs	4	4	4	11	11	15
(f) Depreciation and amortisation expense	91	91	90	278	271	367
(g) Other expenses	594	578	876	1,869	2,099	3,029
Total Expenses	3,507	3,209	4,137	10,455	11,540	15,606
5. Profit before exceptional items and tax from continuing operations (3-4)	1,296	941	1,126	3,890	3,549	4,691
6. Exceptional items (Refer note 4)	(273)	-	-	(273)	(457)	(377)
7. Profit before tax from continuing operations (5+6)	1,023	941	1,126	3,617	3,092	4,314
8. Tax expense from continuing operations						
Current Tax	312	250	310	1,019	979	1,258
Deferred Tax	(49)	(4)	(6)	(52)	(111)	(81)
<b>9. Profit for the period /year from continuing operations (7-8)</b>	760	695	822	2,650	2,224	3,137
10. Profit before tax from discontinued operations	-	-	-	-	1,312	1,312
11. Tax expense from discontinued operations	-	-	-	-	314	314
<b>12. Profit for the period /year from discontinued operations (10-11)</b>	-	-	-	-	998	998
<b>13. Profit for the period /year (9+12)</b>	760	695	822	2,650	3,222	4,135
14. Other comprehensive income (OCI) (Net of Tax) from continuing operations	-	-	-	-	-	72
15. Other comprehensive income (OCI) (Net of Tax) from discontinued operations	-	-	-	-	-	-
16. Total Other comprehensive income (OCI) (Net of Tax) (14+15)	-	-	-	-	-	72
<b>17. Total comprehensive income for the period/year (13+16)</b>	760	695	822	2,650	3,222	4,207
18. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
19. Other equity	-	-	-	-	-	8,376
20. Basic and diluted earnings per share (not annualised) (in ₹)						
Continuing Operations	32.99	30.18	35.69	115.06	96.57	136.21
Discontinued Operations	-	-	-	-	43.33	43.33
Continuing and Discontinued Operations	32.99	30.18	35.69	115.06	139.90	179.54

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 29, 2025

**ARUNKUMAR RAMDAS**  
Digitally signed by  
ARUNKUMAR RAMDAS  
Date: 2025.10.29  
13:12:22 +05'30'

**RACHID AYARI**  
Digitally signed by  
RACHID AYARI  
Date: 2025.10.29  
13:04:17 +05'30'

**Notes:**

1. The above Results have been reviewed by the Audit Committee at its meeting held on October 28, 2025, and approved by the Board of Directors of the Company at its meeting held on October 29, 2025. The statutory auditors have carried out a limited review of the above results for the quarter and nine months ended September 30, 2025.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The Company demerged its Consumer Healthcare business effective June 1, 2024, after obtaining approval of the NCLT. Consequently, financial results for the Consumer Healthcare business are presented as discontinued operations for periods ended September 30, 2024 and December 31, 2024.
4. Exceptional items relate to personnel separation costs of ₹273 million for the quarter and nine months ended September 30, 2025. Comparative amounts were ₹457 million for the nine months ended September 30, 2024, and ₹377 million, net of an ₹80 million reversal, for the year ended December 31, 2024.
5. Effective July 16, 2025, Company entered into a promotion and distribution agreement with Emcure Pharmaceuticals Limited for its Oral Anti-diabetic (OAD) business products.
6. An interim dividend of ₹ 75 per equity share of ₹ 10 for the year 2025 was declared at the meeting of the Board of Directors of the Company held on October 29, 2025.
7. The Company has a single business segment namely 'Pharmaceutical Business'.

SANOFI INDIA LIMITED

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 29, 2025

**ARUNKUMAR**  
**RAMDAS**

Digitally signed by  
ARUNKUMAR RAMDAS  
Date: 2025.10.29 13:12:42  
+05'30'

RACHID  
AYARI

Digitally signed by  
RACHID AYARI  
Date: 2025.10.29  
13:04:51 +05'30'

**RACHID AYARI**  
**WHOLE TIME DIRECTOR & CFO**  
**DIN: 10408699**

October 29, 2025